Monday 8th July 2019
SRUK wins £1,000 Movement for Good award
SRUK has won a £1,000 boost as part of specialist insurer Ecclesiastical's Movement for Good awards, which is giving £1 million to charities this summer.
Thursday 27th June 2019
The role of the lymphatic system in autoimmune disease
Given the role that the lymphatic system plays with the immune system, it has been speculated that lymphatic dysfunction may encourage the development of rheumatic autoimmune diseases, such as scleroderma, lupus and rheumatoid arthritis.
Friday 21st June 2019
Predicting outcomes in fibrotic conditions
Fibrosis is one of the major physical changes that a person living with scleroderma can experience. Its effects are potentially extremely damaging and widespread in the body, it is critical that biomarkers are defined to predict if certain individuals are at risk of developing fibrosis.
Tuesday 11th June 2019
Does epigenetics have a part to play in scleroderma?
A core pillar of SRUK’s 5-year research strategy is identifying causes behind the development of Raynaud’s and scleroderma. Here we've explored the current research into the potential epigenetic causes of autoimmune conditions like scleroderma.
Thursday 6th June 2019
Innovations in the assessment of Raynaud’s Phenomenon
Despite the similarity of initial symptoms in primary Raynaud’s phenomenon (PRP) and secondary Raynaud’s phenomenon (SRP), the long-term implications of SRP mean that it is critical for there to be more effective assessments that can accurately specify which of the two a person may have.
Tuesday 4th June 2019
Hand-arm vibration syndrome: the importance of protecting yourself in the workplace
Prolonged exposure to hand-transmitted vibration (HTV) can result in hand-arm vibration syndrome (HAVS). When associated with secondary Raynaud’s, this is called vibration white finger, where there is damage to nerves, blood vessels and joints in the hand.
Friday 31st May 2019
New internal regulator of the immune system discovered in an SRUK-funded study
SRUK are thrilled to see the results of an investigation, undertaken by an international team of researchers and clinicians, where there has been the identification of a new internal regulator which helps to control the body’s immune response.
Friday 24th May 2019
Boehringer Ingelheim publish new data on experimental ILD drug
Approximately 25% of people who live with systemic sclerosis (SSc) also develop significant pulmonary (lung) involvement within 3 years of diagnosis. Nintedanib could make a considerable difference to the lives of people with this rare and often life-threatening disease.
Thursday 23rd May 2019
6 tips for self-management
Self-management is what an individual can do to manage their condition and to help maintain their wellbeing. How this is approached will differ from person to person, but fundamentally it revolves around making decisions to support a healthy lifestyle, whilst recognising the physical and emotional effects the disease can have.
Tuesday 21st May 2019
Hannah’s Story of Localised Scleroderma
Here's Hannah's story of how overlapping diagnoses of lichen sclerosis, localised scleroderma, hypermobility, fibromyalgia and irritable bowel syndrome changed her life forever.